00:39:28 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-11-08 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018


ListaMERK Equities
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen.
2021-10-14 08:20:00
Bergen, 14.10.2021

Lifecare has been invited to take seat in the Industrial Advisory Board (IAB) at
the 5th International Conference on Manipulation, Automation and Robotics at
Small Scales (MARSS) to be held in Toronto, Canada, July 18-22, 2022. Lifecare
has accepted the invitation.

MARSS is the flagship event for cross-disciplinary R&D communities to discuss
current activities in all areas related to manipulation and automation
(including measurement and characterization) at micro & nano scales, and in all
kinds of small-scale robots and their applications. The 5th annual MARSS is
sponsored by the University of Toronto, the University of Oldenburg and the IEEE
subdivisions IEEE Robotics & Automation Society and IEEE Nanotechnology Council
Advancing Nanotech for Humanity. The IEEE is the world largest technical
professional organization for the advancement of technology carrying the slogan
"Advancing Technology for Humanity".

The nomination of Lifecare to join the IAB of the MARSS conference is an
appreciation of Lifecare's interdisciplinary research and development within the
fields of nanosensing, electronics, chemistry, and robotics employed by the
company in the course of the Sencell sensor development. The already achieved
miniaturization of Lifecare's Sencell sensor for glucose detection is based on a
3DNanoprinting process, which allows to produce strain sensor elements at the
size of a few tens of a nanometer (1 nanometer = 1 millionth of a millimeter) at
the newly established Lifecare Nanobiosensors MEMS & Sensor Research Laboratory
in Reutlingen (Germany). Lifecare Nanobiosensors holds a global license for the
3DNanoprinting technology making it possible to produce and market the complete
overall Sencell device for continuous glucose monitoring at the size of a grain
of rice.

Lifecare is honored by the invitation from the MARSS Steering Committee and
looks forward to interacting with the conference participants to bridge the
communication and support the joint development efforts between the industry,
academia and other stakeholders.

More information of the MARSS conference can be found at

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The Company's patented technology also has the
potential for use in various biomarkers. Lifecare AS is listed on Euronext
Growth (LIFE).

For further information, please contact: Joacim Holter, CEO, Lifecare AS,
joacim.holter@lifecare.no, +47 40 05 90 40

This stock exchange announcement was published by Kine Hereid, Investor
Relations at Lifecare AS, on 14.10.2021 at 08:20 CET.